Gross and net revenue declined sharply year-over-year due to drug shortages, cash flow pressures, and stricter provisioning for doubtful accounts. Adjusted EBITDA turned negative and net loss widened, while leverage increased to 5.2x LTM EBITDA.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.